Everyone is chasing signals. Fundz is what comes next.
Everyone gets the same alerts the same morning. Fundz brings more than a dozen live business signals together on each company, ranks every company against your ICP, and each morning delivers the best few: who to reach out to, why, and who you already know there. Now it answers in Claude too: ask for today’s leads, then write the note in the same window.
Trusted by
OracleSnowflakeCloudflareLinkedInGoogleSalesforce
★★★★★4.8/5 on G2· Since 2015
Tectora, a biotech focused on immunology and inflammation therapies, secured $55 million in Series A funding.
PRIVATEOct 08, 2026
Amount Raised
$55 Million
Round Type
Series A
BiotechnologyHealth Care
Description
Tectora, a biotech company focused on immunology and inflammation therapies, has closed a Series A funding round of $55 million. The company was formed with support from Schrödinger, a computational chemistry platform. This funding will support Tectora's development of therapies in immunology and inflammation. The news has drawn attention to Schrödinger's role in the biotech ecosystem.
Company Information
Company
Tectora
About
Schrödinger (SDGR) is a biotech company involved in immunology and inflammation therapies. The company recently helped form Tectora, which secured $55 million in Series A funding. Schrödinger has a pipeline including SGR-1505 with positive Phase I data. The company operates in drug discovery and predictive toxicology software.
Fundz sees it the moment Tectora raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.